Medical Devices industry cross border M&A deals total $4.64bn globally in Q1 2021

Total medical devices industry cross border M&A deals worth $4.64bn were announced globally in Q1 2021, led by Boston Scientific’s $1.07bn asset transaction with Lumenis, according to GlobalData’s deals database.

The value marked an increase of 2.4% over the previous quarter of $4.53bn and a drop of 23.2% when compared with the last four-quarter average, which stood at $6.04bn.

Comparing cross border M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $2.37bn. At the country level, the Belgium topped the list in terms of deal value at $1.15bn.

In terms of volumes, Europe emerged as the top region for medical devices industry cross border M&A deals globally, followed by North America and then Asia-Pacific.

The top country in terms of cross border M&A deals activity in Q1 2021 was the US with 17 deals, followed by Canada with seven and Germany with seven.

In 2021, at the end of , cross border M&A deals worth $4.64bn were announced globally in medical devices industry, marking a decrease of 720.3% year on year.

Cross Border M&A deals in medical devices industry in Q1 2021: Top deals

The top five cross border M&A deals in medical devices industry accounted for 77.3% of the overall value during Q1 2021.

The combined value of the top deals stood at $3.59bn, against the overall value of $4.64bn recorded for the quarter.

The top five medical devices industry cross border medical devices deals of Q1 2021 tracked by GlobalData were:

1) Boston Scientific’s $1.07bn asset transaction with Lumenis

2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific

3) Koninklijke Philips’ $635m acquisition of Capsule Technologies

4) The $591m acquisition of Oxford Immunotec by PerkinElmer

5) Savaria’s acquisition of Handicare Group for $409.7m.